Extracorporeal membrane oxygenation without systemic anticoagulation: a case-series in challenging conditions

Extracorporeal membrane oxygenation (ECMO) use in patients with active bleedings or traumatic injuries may be challenging because of the risk of refractory haemorrhage related to systemic anticoagulation (SA). Technological advancements, especially heparin coated circuits, allowed ECMO application w...

Full description

Saved in:
Bibliographic Details
Published inJournal of thoracic disease Vol. 12; no. 5; pp. 2113 - 2119
Main Authors Fina, Dario, Matteucci, Matteo, Jiritano, Federica, Meani, Paolo, Kowalewski, Mariusz, Ballotta, Andrea, Ranucci, Marco, Lorusso, Roberto
Format Journal Article
LanguageEnglish
Published China AME Publishing Company 01.05.2020
Subjects
Online AccessGet full text
ISSN2072-1439
2077-6624
DOI10.21037/jtd.2020.04.54

Cover

More Information
Summary:Extracorporeal membrane oxygenation (ECMO) use in patients with active bleedings or traumatic injuries may be challenging because of the risk of refractory haemorrhage related to systemic anticoagulation (SA). Technological advancements, especially heparin coated circuits, allowed ECMO application with a mild or no anticoagulation regimen in some circumstances. We herein report a limited case-series of ECMO application without anticoagulation. ECMO without SA was established in 6 patients. Four of them received veno-arterial mode. Full heparin antagonization with protamine was provided in 3 post-cardiotomy cases. Tip-to-tip heparin-coated ECMO circuit was used in 4 patients, whereas heparin-coated tubing and no heparin-coated cannulas were applied for the remaining subjects. Mean duration of support and pump flow were 10±4 hours and 3.0±0.7 litres respectively. No ECMO related complication or oxygenator failure occurred, nor was clotting of the circuit observed at inspection. All patients were weaned from ECMO and half of them survived and were discharged. Short ECMO duration without anticoagulation was feasible and provided effective cardiopulmonary support in patients with active bleeding or high hemorrhagic risk. Further investigations are needed to evaluate its benefits or limitations for a protracted time, in a wider range of clinical conditions and in larger patient populations.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Contributions: (I) Conception and design: D Fina, M Ranucci, R Lorusso; (II) Administrative support: R Lorusso; (III) Provision of study materials or patients: D Fina, R Lorusso; (IV) Collection and assembly of data: D Fina, M Matteucci, F Jiritano; (V) Data analysis and interpretation: P Meani, A Ballotta, M Kowalewski; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.
ISSN:2072-1439
2077-6624
DOI:10.21037/jtd.2020.04.54